Anti‐Helicobacter pylori Antibody Profiles in Epstein‐Barr virus (EBV)‐Positive and EBV‐Negative Gastric Cancer. Issue 2 (7th August 2015) - Camargo, M. Constanza
Abstract: Background: Helicobacter pylori is the primary cause of gastric cancer, but about 9% of cases harbor Epstein–Barr virus (EBV) in the tumor cells. There is limited evidence on the possible interaction or antagonism between these infectious agents in gastric carcinogenesis. Methods: We compared H. pylori serologic profiles of EBV‐positive (n = 58) and EBV‐negative (n = 111) noncardia gastric cancer patients from the United States National Cancer Institute's International EBV‐Gastric Cancer Consortium. EBV positivity of tumors was assessed by in situ hybridization. Serum levels of 15 antibodies to immunogenic proteins of H. pylori (Cad, CagA, Cagδ, CagM, Catalase, GroEL, HcpC, HP0231, HP0305, HpaA, HyuA, NapA, Omp, UreA, VacA) were assessed using bead‐based multiplex serology. Logistic regression models were used to adjust odds ratios (OR) for country, age, sex, and year of diagnosis. Results: Seropositivity to individual proteins ranged up to 90% overall. Antibodies to Catalase were borderline associated with tumor EBV positivity (adjusted OR = 3.15, p = .0024, Bonferroni corrected p = .036). Distributions of other antibodies did not vary by tumor EBV status. Conclusion: Similarity of host–response indicates the essential etiological role of H. pylori in EBV‐positive gastric cancer.